Up to 30% of patients prescribed treatment to lower LDL-C are intolerant of statins and discontinue taking them^1,2. Additionally, a large segment of the LDL-C population is not at treatment goal³. These patients require additional non-statin therapy or an entirely non-statin alternative.



When considering a non-statin therapy for your patients, whether as add-on or replacement, how important are each of the following traits: oral vs. injectable product, effect on CRP, low risk of new incident diabetes? European and US guidelines differ as do AHA/ACC and AACE/ACE; which guidelines do you follow and why?

• ¹ https://www.mayoclinicproceedings.org/article/S0025-6196(18)30041-7/fulltext


• ² https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960491/


• ³ https://www.tctmd.com/news/ldl-levels-still-too-high-many-statin-treated-patients-pinnacle

Up to 30% of patients prescribed treatment to lower LDL-C are intolerant of statins and discontinue taking them^1,2. Additionally, a large segment of the LDL-C population is not at treatment goal³. These patients require additional non-statin therapy or an entirely non-statin alternative.

When considering a non-statin therapy for your patients, whether as add-on or replacement, how important are each of the following traits: oral vs. injectable product, effect on CRP, low risk of new incident diabetes? European and US guidelines differ as do AHA/ACC and AACE/ACE; which guidelines do you follow and why?

• ¹ https://www.mayoclinicproceedings.org/article/S0025-6196(18)30041-7/fulltext
• ² https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960491/
• ³ https://www.tctmd.com/news/ldl-levels-still-too-high-many-statin-treated-patients-pinnacle

Up to 30% of patients prescribed treatment to lower LDL-C are intolerant of statins and discontinue taking them^1,2. Additionally, a large segment of the LDL-C population is not at treatment goal³. These patients require additional non-statin therapy or an entirely non-statin alternative.



When considering a non-statin therapy for your patients, whether as add-on or replacement, how important are each of the following traits: oral vs. injectable product, effect on CRP, low risk of new incident diabetes? European and US guidelines differ as do AHA/ACC and AACE/ACE; which guidelines do you follow and why?

• ¹ https://www.mayoclinicproceedings.org/article/S0025-6196(18)30041-7/fulltext


• ² https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960491/


• ³ https://www.tctmd.com/news/ldl-levels-still-too-high-many-statin-treated-patients-pinnacle

Up to 30% of patients prescribed treatment to lower LDL-C are intolerant of statins and discontinue taking them^1,2. Additionally, a large segment of the LDL-C population is not at treatment goal³. These patients require additional non-statin therapy or an entirely non-statin alternative.



When considering a non-statin therapy for your patients, whether as add-on or replacement, how important are each of the following traits: oral vs. injectable product, effect on CRP, low risk of new incident diabetes? European and US guidelines differ as do AHA/ACC and AACE/ACE; which guidelines do you follow and why?

• ¹ https://www.mayoclinicproceedings.org/article/S0025-6196(18)30041-7/fulltext


• ² https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960491/


• ³ https://www.tctmd.com/news/ldl-levels-still-too-high-many-statin-treated-patients-pinnacle